Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2016 - 2017)

Historic Non-Current Deferred Tax Liability for CytomX Therapeutics (CTMX) over the last 4 years, with Q3 2017 value amounting to $520000.0.

  • CytomX Therapeutics' Non-Current Deferred Tax Liability rose 136.45% to $520000.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $520000.0, marking a year-over-year increase of 136.45%. This contributed to the annual value of $513000.0 for FY2016, which is 118.34% up from last year.
  • Per CytomX Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $520000.0 for Q3 2017, which was up 136.45% from $539000.0 recorded in Q2 2017.
  • Over the past 5 years, CytomX Therapeutics' Non-Current Deferred Tax Liability peaked at $539000.0 during Q2 2017, and registered a low of $499000.0 during Q4 2014.
  • Moreover, its 4-year median value for Non-Current Deferred Tax Liability was $513000.0 (2016), whereas its average is $513500.0.
  • Examining YoY changes over the last 5 years, CytomX Therapeutics' Non-Current Deferred Tax Liability showed a top increase of 506.82% in 2017 and a maximum decrease of 78.43% in 2017.
  • CytomX Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $499000.0 in 2014, then rose by 1.6% to $507000.0 in 2015, then grew by 1.18% to $513000.0 in 2016, then rose by 1.36% to $520000.0 in 2017.
  • Its last three reported values are $520000.0 in Q3 2017, $539000.0 for Q2 2017, and $514000.0 during Q1 2017.